Diagnosed and Drug-Treated Prevalence of Essential Tremor in Adult Patients: Retrospective Analyses of Two US Healthcare Claims Databases

Objective: To estimate the prevalence of diagnosed and drug-treated essential tremor (ET) in the adult population using two US healthcare claims databases. Background: ET is a chronic, heterogeneous, and progressive neurological disorder that can impact activities of daily living. Few epidemiological studies describe the prevalence of diagnosed or drug-treated ET in the US. Design/Methods: A retrospective cohort study was conducted using Merative™ MarketScan® Research Databases (MarketScan®) and Symphony Integrated Dataverse (IDV®) (01/01/2016–12/31/2019) to estimate the number of US adults (age ≥18 years) with ET. ET diagnosis was defined as ≥2 medical claims containing ICD-10-CM code G25.0 ≥1 and ≤365 days apart. Patients with drug-treated ET were defined as those with ≥180 days of observability following ET diagnosis who subsequently received any ET medication in 2019. Age-adjusted prevalence was used to estimate the number of US adults with diagnosed and drug-treated ET. Results: Estimated age-adjusted numbers (95% CIs) of US adults diagnosed with ET were 782,800 (770,666–795,119) and 525,115 (522,893–527,457) using MarketScan and IDV, respectively. The majority of those diagnosed with ET also received pharmacological treatment for ET. Specifically, the estimated proportions (95% CIs) of adult patients with ET who were drug-treated were 73.8% (73.1%–74.4%) and 74.8% (74.6%–75.0%), respectively. Estimated age-adjusted numbers (95% CIs) of adult patients with drug-treated ET were 588,489 (578,043–599,067) and 391,680 (389,570–393,668), respectively. Beta-blockers (64% and 61%, respectively) and anticonvulsants (53% and 61%, respectively) were the most common drug classes prescribed among those treated. The most frequently prescribed beta-blocker and anticonvulsant were propranolol (41% and 35%, respectively) and primidone (27% and 32%, respectively). Conclusions: ET affects many US adults, most of whom are treated. Many patients receive regimens not indicated as first-line for ET, suggesting the need for novel therapies indicated for this condition. Disclosure: Mr. Saad has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Saad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Evidinno Outcomes Research Inc.. Mr. Saad has received stock or an ownership interest from Jazz Pharmaceuticals. Dr. Markowitz has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Markowitz has stock in Jazz Pharmaceuticals, UCB Pharmaceuticals, J&J. Ms. Gibbs has received personal compensation for serving as an employee of Aetion, Inc. Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has received stock or an ownership interest from D F. Dr. Ni has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Dr. Ni has stock in Jazz Pharmaceuticals. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Acorda. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Cala Health. Dr. Pahwa has received personal compensation in the range of $0-$499 for serving as a Consultant for Global Kinetics. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Kyowa. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sunovion. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allevion. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuroderm. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Photopharmics. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wren. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Biohaven. The institution of Dr. Pahwa has received research support from Boston Scientific. The institution of Dr. Pahwa has received research support from EIP. The institution of Dr. Pahwa has received research support from Global Kinetics. The institution of Dr. Pahwa has received research support from Amneal. The institution of Dr. Pahwa has received research support from Neuraly. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Pharma 2B. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theranexus. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Voyager. The institution of Dr. Pahwa has received research support from Neuroderm. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acorda. Dr. Lyons has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Supernus. Dr. Lyons has a non-compensated relationship as a President with International Essential Tremor Foundation that is relevant to AAN interests or activities. Dr. Baladi has stock in Jazz Pharmaceuticals . Ms. Lin has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Ms. Lin has stock in Jazz Pharmaceuticals. Ms. Lin has received publishing royalties from a publication relating to health care.